Stock Upgrades Highlight Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  25 Dec 2025
 

•   ADEA  
   
  0.00%
•   ANNX  
   
  0.00%
•   CECO  
   
  0.00%
•   COST  
   
  0.00%
•   COYA  
   
  0.00%

$ADEA Adeia continues to earn analyst support, with Maxim Group maintaining its Buy recommendation and pointing to nearly 18% upside. The consistency here is notable, as analysts appear comfortable with Adeia IP-driven revenue model and see steady progress rather than a one-off catalyst.

$ANNX Annexon stands out sharply after Chardan Capital initiated coverage with a Buy and an eye-catching upside projection. This reflects strong belief in the pipeline optionality, and while speculative, the magnitude of the target underscores how asymmetric biotech upgrades can be when sentiment turns positive.

$CECO CECO Environmental benefited from a higher price target and maintained Outperform rating, signaling that analysts see room for continued upside despite recent strength. The update suggests confidence in execution and demand visibility rather than a short-term trade.

$COST Costco earned a Buy rating from Northcoast on expectations of EPS growth and margin expansion. This reinforces the narrative that even at scale, COST continues to deliver operational leverage that justifies premium valuations in the eyes of analysts.

$COYA Coya Therapeutics remains firmly on analysts’ radar after D. Boral Capital maintained a Buy with substantial upside implied. As with many early-stage biotech names, this reflects belief in the science more than current revenues, making COYA a higher-risk but potentially higher-reward upgrade.

$CRM Salesforce saw its Buy rating reiterated as analysts highlighted AI-driven growth, particularly around Agentforce. The message here is clear: CRM AI strategy is increasingly viewed as a durable growth engine rather than marketing hype.

$CRSP CRISPR Therapeutics received reaffirmed Buy and Market Outperform ratings, underscoring confidence in its platform and long-term commercialization potential. The consistency across firms suggests a broad-based belief that CRSP story is intact despite sector volatility.

$EPM Evolution Petroleum gained fresh coverage with a Buy, reflecting optimism around cash flow and asset quality. Energy upgrades like this tend to attract income-focused traders looking for stability with upside.

$FIVN Five9 maintained its Buy rating as analysts pushed back on bearish tech narratives, emphasizing sustained AI demand in contact centers. The tone suggests confidence that FIVN can navigate macro noise while continuing to grow.

$IVVD Invivyd saw its Buy rating reiterated with significant upside implied, reinforcing bullish sentiment around its pipeline and strategic positioning. For traders, this kind of reaffirmation often keeps speculative interest alive.

$LRCX Lam Research kept its Buy rating despite limited upside implied, signaling that analysts still view the stock as fundamentally sound even if near-term gains may be more measured.

$MBUU Malibu Boats entered coverage with a Buy, reflecting optimism around normalization in discretionary demand. This kind of initiation often sparks renewed interest in under-followed consumer names.

$NYT The New York Times maintained a Buy rating, though with limited upside, suggesting analysts remain supportive of the long-term digital subscription story while acknowledging valuation constraints.

$PERI Perion Network received Buy initiations, reflecting confidence in its strategic positioning despite a volatile advertising landscape. Analysts appear to see resilience rather than cyclical decline.

$PLUG Plug Power drew attention after a rare upgrade tone shift, marking a potential inflection after years of skepticism. While risks remain high, the change in analyst posture itself is notable.

$SGHT Sight Sciences maintained a Buy rating, though with modest downside implied, suggesting analysts are supportive but cautious on near-term performance.

$SION Sionna Therapeutics entered coverage with an Outperform rating, signaling early confidence in its clinical approach even as near-term upside appears limited.

$SMCI Super Micro Computer remains in focus as analysts assess its rack-scale AI strategy, viewing volume growth as a potential offset to margin pressure and reinforcing longer-term growth confidence.

$TEVA Teva received credit rating upgrades from S&P and a positive outlook from Moody, marking tangible progress in its turnaround narrative. For equity traders, credit upgrades often act as quiet but powerful validation.

$TSLA Tesla maintained its Buy rating despite downside implied, reflecting continued belief in the strategic position even as expectations moderate.

$VZLA Vizsla Silver initiated coverage with a Buy, reflecting constructive views on its asset base and silver exposure, albeit with measured upside.

$WYFI WhiteFiber maintained a Buy rating following a major agreement, reinforcing confidence in its fast-deploy AI infrastructure model.

View All Headlines